These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19640613)

  • 1. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
    Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
    Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors.
    Deng XQ; Wang HY; Zhao YL; Xiang ML; Jiang PD; Cao ZX; Zheng YZ; Luo SD; Yu LT; Wei YQ; Yang SY
    Chem Biol Drug Des; 2008 Jun; 71(6):533-9. PubMed ID: 18410307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
    Li X; Wang L; Long L; Xiao J; Hu Y; Li S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
    Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.
    Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
    Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
    J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jang Y; Lee HS; Park HJ; Yoo J
    J Med Chem; 2007 Jun; 50(13):3143-7. PubMed ID: 17552507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
    Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
    Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).
    Singh J; Ling LE; Sawyer JS; Lee WC; Zhang F; Yingling JM
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):437-45. PubMed ID: 15338953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
    Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors.
    Kim DK; Choi JH; An YJ; Lee HS
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.
    Xie HZ; Liu LY; Ren JX; Zhou JP; Zheng RL; Li LL; Yang SY
    J Biomol Struct Dyn; 2011 Aug; 29(1):165-79. PubMed ID: 21696232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
    Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
    J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.